Windtree Therapeutics, Inc. (NASDAQ:WINT) Expected to Announce Earnings of -$0.11 Per Share

Wall Street analysts expect Windtree Therapeutics, Inc. (NASDAQ:WINTGet Rating) to report earnings of ($0.11) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Windtree Therapeutics’ earnings. Windtree Therapeutics reported earnings of ($1.42) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 92.3%. The firm is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Windtree Therapeutics will report full-year earnings of ($0.68) per share for the current year, with EPS estimates ranging from ($1.07) to ($0.29). For the next fiscal year, analysts expect that the firm will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.86) to ($0.48). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Windtree Therapeutics.

Windtree Therapeutics (NASDAQ:WINTGet Rating) last issued its earnings results on Thursday, March 31st. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.13).

Shares of NASDAQ WINT opened at $0.52 on Monday. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.36. Windtree Therapeutics has a 12 month low of $0.49 and a 12 month high of $3.40. The stock has a 50 day moving average of $0.96 and a 200-day moving average of $1.29. The company has a market capitalization of $15.17 million, a P/E ratio of -0.25 and a beta of 0.29.

Hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new stake in shares of Windtree Therapeutics during the 4th quarter worth about $66,000. Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of Windtree Therapeutics by 15.7% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 110,500 shares of the company’s stock worth $228,000 after buying an additional 15,000 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Windtree Therapeutics by 129.8% during the 3rd quarter. Geode Capital Management LLC now owns 158,747 shares of the company’s stock worth $327,000 after buying an additional 89,665 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Windtree Therapeutics by 28.6% in the 3rd quarter. Renaissance Technologies LLC now owns 187,400 shares of the company’s stock valued at $386,000 after purchasing an additional 41,700 shares during the period. 11.37% of the stock is owned by institutional investors and hedge funds.

Windtree Therapeutics Company Profile (Get Rating)

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension.

Featured Stories

Get a free copy of the Zacks research report on Windtree Therapeutics (WINT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.